Could a supplement and drug combo help treat obesity?

NCT ID NCT05713799

Not yet recruiting Disease control Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 35 times

Summary

This Phase 2 trial tests whether combining the supplement alpha-lipoic acid with the drug mirabegron can improve how the body processes sugar in people with obesity. Sixty adults aged 18 to 65 with a BMI between 30 and 45 will take the combination or a placebo for 4 weeks. The study measures changes in insulin sensitivity to see if this approach could lead to a new treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: alpha-lipoic acid and mirabegron
What this could lead to: If it works, this could point toward a new combination treatment for obesity and insulin resistance that is safe and widely available.
What could go wrong: This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The combination may not improve insulin sensitivity more than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INSULIN RESISTANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INSULIN RESISTANCE OBESITY

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.